Long-Term Clinical and Molecular Follow-up of Large Animals Receiving Retrovirally Transduced Stem and Progenitor Cells: No Progression to Clonal Hematopoiesis or Leukemia
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
There has been significant progress toward clinically relevant levels of retroviral gene transfer into hematopoietic stem cells (HSC), and the therapeutic potential of HSC-based gene transfer has been convincingly demonstrated in children with severe combined immunodeficiency syndrome (SCID). However, the subsequent development of leukemia in two children with X-linked SCID who were apparently cured after transplantation of retrovirally corrected CD34+ cells has raised concerns regarding the safety of gene therapy approaches utilizing integrating vectors. Nonhuman primates and dogs represent the best available models for gene transfer safety and efficacy and are particularly valuable for evaluation of long-term effects. We have followed 42 rhesus macaques, 23 baboons, and 17 dogs with significant levels of gene transfer for a median of 3.5 years (range 1-7) after infusion of CD34+ cells transduced with retroviral vectors expressing marker or drug-resistance genes. None developed abnormal hematopoiesis or leukemia. Integration site analysis confirmed stable, polyclonal retrovirally marked hematopoiesis, without progression toward mono- or oligoclonality over time. These results suggest that retroviral integrations using replication-incompetent vectors, at copy numbers achieved using standard protocols, are unlikely to result in leukemogenesis and that patient- or transgene-specific factors most likely contributed to the occurrence of leukemia in the X-SCID gene therapy trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Self-citationTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., & Moen, R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1125 · Cited by 532
Self-citation
Cited by
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Sinn, P. L., Sauter, S. L., & McCray, P. B. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302570 · Cited by 322
Chemically Controlled Protein Assembly: Techniques and Applications
Fegan, A., White, B., Carlson, J. C. T., & Wagner, C. R. (2010) · Chemical Reviews · doi:10.1021/cr8002888 · Cited by 294
Hematti, P., Hong, B.-K., Ferguson, C., Adler, R., Hanawa, H., Sellers, S., Holt, I. E., Eckfeldt, C. E., Sharma, Y., Schmidt, M., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020423 · Cited by 265
Self-citationGenotoxicity of Retroviral Integration In Hematopoietic Cells
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.001 · Cited by 258
Self-citationStem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114
“In this study, no evidence of progression toward oligoclonal or monoclonal hematopoiesis was observed [79].”
BackgroundSelf-citationDevelopment of Gene Therapy for Thalassemia
Nienhuis, A. W., & Persons, D. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011833 · Cited by 38
“Although the risk of insertional mutagenesis with proto-oncogene activation was recognized when the trials were initiated, this complication was not observed in murine models or in large animal studies over the years (Kiem et al. 2004; Nienhuis et al. 2006).”
BackgroundSelf-citationHayakawa, J., Ueda, T., Lisowski, L., Hsieh, M. M., Washington, K., Phang, O., Metzger, M., Krouse, A., Donahue, R. E., Sadelain, M., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.186 · Cited by 9
“A reduction in absolute HSC numbers could account for the fall in marking derived from the long-term repopulating cell compartment as the gene marking level at 4–6 months or greater post-transplantation represents the ‘‘true HSC’’ marking level (Kim et al. , 2000).”
Self-citation
Metadata
- Authors
- Kiem, H.-P., Sellers, S., Thomasson, B., Morris, J. C., Tisdale, J. F., Horn, P. A., Hematti, P., Adler, R., Kuramoto, K., Calmels, B., Bonifacino, A., Hu, J., von Kalle, C., Schmidt, M., Sorrentino, B., Nienhuis, A., Blau, C. A., Andrews, R. G., Donahue, R. E., & Dunbar, C. E.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 9
- Issue
- 3
- Pages
- 389-395
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2161347101
- Cited by
- 92
- References
- 3
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.